To bolster its technical capabilities, Spore.Bio has established a partnership with the Pasteur Institute and acquired competitor Greentropism.

Currently, Spore.Bio has secured around a dozen clients globally, with approximately half based in the United States, and has opened a waitlist due to high demand.

The startup utilizes a pre-trained deep learning algorithm designed to improve the speed and efficiency of microbiological diagnostics, which is critical in healthcare and research settings.

Spore.Bio's efforts are particularly timely as the FMCG industry has seen a rise in product recalls, which increased by over 20% in 2024, causing significant financial losses.

Founded in 2023, Spore.Bio is a deeptech startup based in Paris, co-founded by Amine Raji, Maxime Mistretta, and Mohamed Tazi, who bring expertise from food manufacturing and microbiology.

The company has successfully raised $23 million in a Series A funding round, led by Singular, to enhance microbiology testing using machine learning.

Their innovative technology allows for immediate, on-site microbiological testing, significantly speeding up the traditional process that typically takes five to 20 days.

The company's technology aims to prevent contamination incidents in the food and beverage industry, which can lead to costly recalls and damage to brand reputation.

CEO Amine Raji emphasizes the transformative potential of their AI-based technology in improving safety in consumer products worldwide.

Spore.Bio aims to revolutionize pathogen testing in the fast-moving consumer goods (FMCG) industry, reducing detection time from days to mere minutes.

Looking ahead, Spore.Bio plans to expand its workforce to 50 employees by the end of 2025 and increase its presence in the US market.

This funding round also saw participation from notable investors such as Point 72 Ventures and Lord David Prior, bringing total investments to $31.3 million.